Why Tempus AI Inc. (TEM) Went Up On Wednesday

We recently published a list of These 10 Firms Topped Wednesday’s Trading. In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that topped Wednesday’s trading.

Wall Street’s major indices rebounded anew on Wednesday as worries about tariff policies and the Federal Reserve’s independence tapered off after President Donald Trump assured that he had no intentions of ousting Jerome Powell.

The Nasdaq surged by 2.5 percent, the S&P 500 rose by 1.67 percent, while the Dow Jones increased by 1.07 percent.

Ten companies mirrored the broader market optimism as optimistic investors resumed pouring funds into their stocks. In this article, we have identified Wednesday’s 10 best-performing stocks during the intra-day trading and detailed the reasons behind their strong performance.

To come up with the list, we considered only the stocks with more than $2 billion in market capitalization and $5 million in intraday trading volume.

A healthcare provider holding an MRI scan of a patient with a traumatic brain injury.

Tempus AI Inc. (NASDAQ:TEM)

Tempus AI extended its winning streak for a third straight day on Wednesday, adding 18.69 percent at intra-day trading before ending the day just up by 14.62 percent at $49.55 apiece after bagging a $200-million partnership with AstraZeneca and Pathos AI for the development of a multimodal foundation model in oncology.

In a statement, TEM said the total amount includes data licensing and model development fees.

The model, which will utilize TEM’s de-identified oncology data, will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.

Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care.

“Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,” said TEM CEO Eric Lefkofsky.

“Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape. We look forward to working with AstraZeneca and Pathos to apply AI-enabled solutions to advance therapies in an effort to help patients live longer and healthier lives,” he added.

Overall, TEM ranks 1st on our list of firms that topped Wednesday’s trading. While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TEM but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.